MedTrace Logo

Donepezil Compared to Placebo in Patients With Chronic Neuropathic Pain

NCT01743976 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2021-03-02

Study results available
· View outcomes & findings →

Summary

Based on laboratory studies, donepezil will improve pain relief more than placebo in patients with chronic neuropathic pain who are currently taking gabapentin or pregabalin.

Conditions

  • Neuropathic Pain

Interventions

DRUG

Donepezil

donepezil 5 mg once daily for 6 weeks

DRUG

Placebo

placebo or sugar pill will be taken once daily for 6 weeks

Sponsors & Collaborators

  • National Institute of Neurological Disorders and Stroke (NINDS)

    collaborator NIH

  • Wake Forest University

    lead OTHER

Principal Investigators

  • James C Eisenach, M.D. · Wake Forest University Health Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-12-31
Primary Completion
2013-10-23
Completion
2013-10-23
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01743976 on ClinicalTrials.gov